Good afternoon, everyone. Thank you for joining Fosun International 2022 Interim Results Announcement. I'm the General Manager of Capital Market and IR of Fosun International. I'm Sun Lu. First of all, I would like to introduce our Fosun International's management team. They are the Chairman of Fosun International, Mr. Guo Guangchang. Hello, everyone. The Executive Director, Co-Chairman of Fosun International, Mr. Wang Qunbin. Hello, everyone. The Executive Director, Co-CEO of Fosun International, Mr. Xu Xiaoliang. Hello, everyone. Thank you. Executive Director and Co-CEO of Fosun International, Mr. Chen Qiyu. And we also have Executive Director, Executive President, and the CFO of Fosun International, Mr. Gong Ping. Hello, everyone. This announcement will be divided into two days, and today, Fosun International management team will introduce the results in the first half of this year and the corporate strategy and business outlook. Tomorrow morning, the executives responsible for four segments will introduce the results and the business and for the first half of this year, and also strategy. First of all, I would like to give the floor to Mr. Gong Ping, CFO of Fosun International, about the financials and also H1 in 2022. Please, Mr. Gong. Hello, everyone. Dear investors and analysts and shareholders, and our friends, and good afternoon. Today, we are very honored to represent the Fosun International management team to introduce the interim results in 2022. Well, in the first half of this year, as we know that because of geopolitical and also capital market and also the resurgence of COVID-19, there are a lot of challenges. For Fosun International, based on our four engines and our strategy, we have seen very stable growth in the first half of this year. Our total revenue amounts to more than CNY 28.2 billion, up by more than 70%. FTG increased by more than 131%. Also, for 10-year CAGR for total revenue up by 12%. Also in the overseas market, we have seen the increase in 31%. The net profit attributable to the owners of the parent amounting to CNY 2.7 billion and down by 32.67%. Also we can see the industrial operation profit down by more than 35%. Because of the fluctuation in the capital market and also the devaluation of the investment assets, but that is not a loss of cash flow. That is primarily about the valuation. We have also seen the 10-year CAGR of net profit attributable to the owners of the parent and 6%. Here you can also see that we have the enterprise and operation profit this year. Based on the net profit attributable to the owners of the parent, and also in addition to the industrial operational profit, we have also introduced the idea of enterprise and operational profit. Because for our group, and because in for all our subsidiaries, we have removed these contribution of the operation subsidiaries. We can also see that this is the profit contribution of the major members of the group. Despite all these uncertainties and our enterprise and operational profit amounts to CNY 2.33 billion, up by more than 35.5%. The ten-year CAGR of enterprise and operation profit is 6%. The investment of technology and innovation is also increasing and up by 21%, amounting to CNY 4.6 billion. We have also seen 414 million for the number of operational members. For all our four business and segments based on all these consideration, despite all these uncertainties, and despite the pandemic, and we can see the continuous growth of all these in the four segments. Up by 21% for the health, and also more than 70% for the wealth, and more than 30% in growth for happiness, and more than 44% increase for the intelligent manufacturing. We have also seen the growth of the international travel business, and we have also seen the growth from the FTG. You can see that in the Yuyuan, and you can see basically flat, and also for the Fosun Pharma up by 26%. Fosun Insurance Portugal up by 14% and Pramerica down by 1% and FTG up by 131%. Thanks to the overseas business growth. Despite the fluctuation in the capital market, we still have seen very stable level. You can see 4.5% for the average cost of the debt at a low level. We have CNY 17.67 billion for the fundraising in the open market during the reporting period. We also have very sufficient cash and bank balance and term deposits. Our unadjusted NAV decreases slightly due to the impact of the secondary market volatility, but still HKD 24.2 per share. Our leverage ratio rises slightly, but it is still under control. Overall speaking, I know that you are very keen that in terms of the credit rating, it is still very stable at this moment despite the market fluctuation. We continue our financial strategy. In order to improve on our rating, we plan to steadily and orderly reduce the debts year by year from 2022 to 2025, extend the duration of debt, increase the dividend upstream from subsidiaries, and control the headquarters overhead, thereby steadily optimizing the credit indicators and consolidating the ability of steering through the economic cycles. We timely and orderly dispose of the non-strategic and the non-core assets. We continue to strike the balance between the investment and divestment. In this regard, we continue to diversify our assets, and in order to maintain the cross-region and cross-industry asset portfolio to diversify our risks, and we will continue to have our core subsidiaries. At the same time, we have also done a lot to enhance the transparency of the capital structure and asset allocation. You can see that divestment at the group level continues to outnumber the investment in the first half of this year. In the group level, that is a divestment higher than investment. It doesn't mean that we do not make any investment in the portfolio companies, but we continue with an M&A for our Fosun Insurance Portugal, and we have acquired the La Positiva Seguros y Reaseguros, the remaining 40% of the shares, the third largest insurer in Peru, and also in the H1. We have completed syndicated loans and nearly $900 million. For our Fosun Pharma, we successfully completed the group's first overseas sustainability and syndicated loan with an amount of $400 million. We have also signed a strategic agreement with HSBC, so we can also receive the trust from our partners. We have also leveraged the repurchase offers and secondary market purchases. We have purchased our offshore bonds prior to maturity and proposed on Fosun Pharma by July. We have also raised a total of more than CNY 4.4 billion for the non-public offering. In terms of AI platform of Fosun Proxima, we're committed to building a medical AI industrial platform for our Lanvin Group. We have completed the merger with Primavera Capital, and we plan to be listed in the New York Stock Exchange. For Wenxin under intelligent manufacturing. We have completed a non-public offering of shares amounting to more than CNY 1.475 billion. Despite the volatility, we haven't seen the slight decline of our NAV, but after the adjustment, it is still much higher than the share price and can also demonstrate our investment value. Over the past 15 years, the total dividend payout is more than HKD 25.2 billion. We continue to consider the dividend payout. Now after the introduction to our financials, on behalf of our co-CEO, Mr. Chen Qiyu, I would like to give you some further introduction to our business segments, because Mr. Qiyu just arrived at the Hong Kong airport. There was a little delay of his flight. That's why on behalf of Mr. Chen Qiyu, I'm going to introduce our business segments. First of all, the health segment. In the health segment, we have our pharmaceuticals, medical device and diagnostics, health services and products. Then across the world, we continue to make innovation in order to provide a one-stop scenarios. In the first half for our health business, you can see very robust growth up by 21%. In terms of the net profit attributable to the shareholders recorded CNY 287 million, down by 78.6%. That is primarily due to the fluctuation in the secondary market positions. For all the other portfolio companies, take Fosun Pharma, for example, in H1. The revenue amounted to more than CNY 21 billion, up by 26%. You can also see the R&D investment is also increased by 23% and amounted to CNY 2.4 billion. Also for Fosun Pharma, we can also see that the pharmaceutical manufacturer revenue amounts to more than CNY 14 billion. For the devices and the diagnostics, more than CNY 4 billion. For our health services revenue amounted to more than CNY 2.92 billion. While we are coping with the COVID-19, we have also identified more investment opportunities in the COVID-19 and in the post-COVID-19 era, and in terms of the medicine for COVID-19. In July this year, together with Genuine Biotech, we have established the cooperation on the joint development of the first approved oral small molecule COVID-19 drug, Azvudine, and together with Sinopharm. We will continue to promote the coverage of the national channel network. The medicine has already been transported to different places. We have been authorized in MPP, and then we can supply the MSPs and oral drug into more than 105 low- and middle-income countries. We have supplied Pfizer's oral drug against the COVID-19 and Paxlovid. We are working with the Kintor Pharma to develop the commercialization in Africa. We have provided the detection solutions against the COVID-19, and it is also on the white list in Europe. For Comirnaty. It has already been sold by more than 30 million. In April and in May, it has also been sold for those children aged five to 11 years old in Macau and in Taiwan. In August, it was also approved for the vaccination of the kids between six months and four years old in Taiwan, China. In terms of R&D, there are some highlights here in terms of R&D investment. After all our cultivation, we have reaped the fruits and we made a lot of investments on R&D. Here you can see in terms of the growth rate is more than 20%. We have seen the contribution by the high-quality innovative R&D. In March this year, the first indication, and that is HANSIZHUANG for the PD-1 inhibitor and was approved. Just for three months, the sales revenue amounted to more than CNY 76 million. Also for Yikaida, received the domestic clinical trial approval for the second-line treatment in August. An mRNA Comirnaty approved by FDA globally. Also in terms of our self-developed HANLIKANG, HANQUYOU, HANDAYUAN, and HANBEITAI, and HANSIZHUANG, they have also been launched in the market. In terms of the devices and diagnostic products, you can see in terms of LMNT one and anti-hair loss product, and also COVID-19 detection kit and the monkeypox virus detection kit has also been launched. Also in terms of global operation, we continue to dive into details. For example, in H1 in terms of the international revenue, it amounts to more than 37%. Together with Amgen, we have received exclusive commercialization license. For Shanghai Henlius, we have also entered into the licensing and the supply agreement for various products with companies such as Organon. In the United States, we have established our second headquarters in the U.S. In Africa, we have set up five regional centers and about 800 people. In India, we continue to promote Gland Pharma to become the biological drug and CDMO and complex preparations and difficult injections. Compared with our peers in China, we are taking the leadership. We will continue to compete in the global arena. For the pharmaceutical revenue structure, it is optimized gradually. Here you can see that in terms of the optimized pharmaceutical and in terms of the innovative and also the biologics contributed to continuous high growth in H1. You can see the new and recently launched products account for more than 25%. HANQUYOU sales revenue amounts to CNY 813 million, up by more than 150%. SUKEXIN witnessed the revenue up to more than CNY 360 million. Also for HANSIZHUANG and HANLIKANG, and then also for all the other products you can see in a very high sales revenue. In terms of the innovation, we have already borne the fruits. For the medical devices and medical diagnostics, and for our own proprietary brands, it is on the rise. Take the Sisram, for example, for the medical cosmetology, and we have also promote the cosmetic products and et cetera. We continue to work with the Intuitive. We set up a joint venture, the Intuitive Fosun. We have set up a da Vinci center and in order to provide a learning and training platform. We have installed 24 units of da Vinci surgical robots. In August, the construction of the Intuitive Fosun medical robot manufacturing R&D center officially commenced. In terms of the medical diagnostics, we have also set up our R&D and manufacturing capabilities. In terms of the medical service and health management, we continue to make evolution. For our health care services, we have controlled 19 hospitals, and we have more than 5,000 beds. We also continue to synergize our resources with the international partners. Currently, we have more than 200,000 online doctors. Then we have also completed the offline operation in Guangzhou. We have also provided the proactive services. Here you can see the health and those insurance, wellness and health management, and they have also been synergized. For the second part, I'd like to talk about is our happiness segment here. As you can see, we have a diversified product portfolio, and we have, for instance, a consumer brand and also tourism leisure. For instance, we have a jewelry fashion, we have CN platform, we have cultural dining, and also we have sports and e-sport. In tourism leisure, we have a tourism destination, and also we provide a resort and also hotel. We also provide overall services and solution. As you can see, the total revenue is CNY 32.07 billion and increased by 12.5% year-on-year. This is due to the strong recovery from overseas markets. We have two groups. We have Yuyuan, and also we have FTG. Later on, we will have a deep dive into each of them. We have Fosun Sports. We have Baihe Jiayuan and Yuyuan. Due to the pandemic, because Yuyuan is located in Shanghai, and due to the resurgence of the pandemic, actually we have a very stressful quarter two. However, in quarter one, it has a great quarter, and therefore it has achieved growth of 22.01. If you look at the consumer business, it has a high profitability. It is because we have diversified the product matrix and it has increased the profitability to 13.69%. If we look at jewelry and also fashion, again, it is a very strong segment as well. If we look at the revenue, it has increased by. It has a positive growth of 2.3%. We have further expanded our stores. In total, it is more than 4,000, and it is among the top four in China. We have the first boutique store of Lanvin, which is located in Shanghai. In terms of liquor, still Shede and Jinhui Liquor in H1, and they have achieved an increase of 26.4% year-on-year. Especially we have the Tuopai brand. For Jinhui, it has further diversified its portfolio, and also it has increased its revenue proportion in the high pricing segment. If we look at beverage and also food, Song He Lou, it has opened a new store for 12, and also it has entered into Wuhan and also Tianjin. For holiday, it has increased... It has enjoyed a revenue growth of 131%, and especially due to a strong growth of the Club Med business in Europe and also Middle East and also Americas. It also has a wonderful summer vacation, and it has increased its liquidity and also the global revenue from FTG. In China, we also see a strong rebound. For instance, in July, Atlantis Sanya and also Lijiang Holiday Town, and all have achieved a record-breaking year months. For FTG, we have a global business. In China and also in overseas market, we have different policies for the pandemic. If we look at Club Med, it has a strong recovery. Especially since July, the rebound, the recovery is accelerated and also the capacity has achieved more than 85%. If we look at average beds, actually the price is 40% higher than that of 2021. 53 Club Med resorts were in operation worldwide in June 2022. Atlantis Sanya in July also has a rebound, a very strong recovery. If we look at the revenue, it is up by 44% year-on-year. For FOLIDAY Town Lijiang in H1, its average capacity is more than 40%. Due to the location of the FOLIDAY Town in China, it is more or less impacted by our pandemic control. Thomas Cook, especially Thomas Cook U.K., and in H1, we see the restriction is lifted and therefore the revenue has increased to CNY 700 million. We see the order increased by 4.7x. We have expanded the brand into, for instance, Europe and also like the Dutch market and also the Belgium market and also the German market. For some fashion, we use a SPAC to get listed in the New York Stock Exchange. In terms of the top line and also bottom line, both has been increasing. In 2022 compared with 2021, we see a 37% of growth. For our Lanvin, its revenue increase is 120%. In terms of the channel, we have Jingdong flagship, and also we have IFC, and also Harbour City in Hong Kong established. Also we have Sergio Rossi in the Greater China. It has released its new jelly capsule series of Sergio Rossi. Also for the other two companies, Baihe Jiayuan, and also we have Fosun Sports. Baihe Jiayuan, its revenue is experiencing a slightly downward trend. However, we have the online business booming, and it has increased its followers by 9%, and also the registered number is increased by 15%, which is more than 500 million now. It has finished its brand optimization. For the sports group, we have Wolves, and also we have Esports. For Esports, we have again three championship. We have achieved record-breaking months as well, or quarter as well. For Wolves, it ranked at 10th place in the 2022 season. For the third-party is our wealth, and in terms of insurance and also asset management, as you can see, we have improved our efficiency and also the rate of return. For insurance and also investment, we have a Fosun Hive, and also we have the third-party asset management platform. In the total revenue is CNY 22.97 billion, which is up by 16.9% year-on-year. The net profit attributable to the owners is slightly down due to the secondary market fluctuation. For Fidelidade, in total, it has achieved a 12.8% growth. Also for HAL, its revenue is CNY 200 million and also increased by 40%. This is mainly due to our M&A and also consolidation. For Fosun Insurance Portugal, its overseas income attribute contributes to 10% for the first time, and this shows our globalization has achieved a milestone. Also for our core portfolio companies, they have registered double-digit growth rate. For instance, like Fidelidade and also Peak Re. Peak Re, its policy has increased by 58%. Also for Pramerica and also for Fosun Health, they are of a relatively small scale. However, with our very diversified consumption scenarios and also portfolio, they have achieved a wonderful growth as well. For both Pramerica—Fosun Pramerica, its new policy has increased by 7%. Also 938 policies brought in from Fosun Care Community. For Fosun Health, the total premium revenue growth is 13%. All the indicators are very satisfactory. If we look at investment and also the third-party asset management, we utilize our HAL resources and also our PE and also VC platforms. They are RZ Capital and also Fosun Capital and also Fosun Hani Securities and also our Rio Bravo Investimentos and also Guide Investimentos in Brazil and also other countries in Latin America. They all have achieved wonderful results, especially for Fosun Hive. We have a sluggish property market in China. However, they, Fosun Hive has reduced their exposure. Also in terms of the third-party asset management, we have made a preemptive strike. Therefore, if we look at Hive domestic and also Hive overseas, we have created synergy in the overseas capital market and the domestic capital market. This shows our capability in terms of globalization and also diversification. As you can see, we have seen the asset under management increase substantially, both for the domestic and also for the overseas Hive business. For the fourth part is our intelligent manufacturing segment. It covers, for instance, steel making and also industrialization, digitization and for the grain resource industry. In terms of manufacturing and our total revenue has increased by 44%. Also for Nanjing Iron & Steel, it is slightly downward. It is down by 9.59% year-on-year, and it is mainly due to the blast furnace overhaul and also the steelmaking furnace maintenance, which has decreased by 8.55%. The net profit attributable to the parent also a slight decrease of 34%. However, it is still better than the 50% decline in the industry. Hainan Mining and for the total revenue is CNY 2.748 billion and up by 34.35%. If you look at our Easun Technology, it has obtained orders from many domestic manufacturers and also has entered into industrial fields like construction, machinery and also automotive. For JEVE Power, it has received a notification from Geely Commercial Vehicles and the SAIC. BESINO is in the preparation for IPO. If we zoom in to look at Nanjing Iron & Steel, in terms of its advanced steel materials, its revenue is increasing as well. We are managing the ESG. If you look at FTSE Russell, its rating has increased for Nanjing Iron & Steel from 1.6 to 2.2, which is ranking among the top three among Chinese steel companies. The growth margin has increased by 60 basis points as well. We have the so-called full industrial chain development strategy, and Nanjing Iron & Steel embark on the digitization journey. We have now the Indonesia coking plant also enter into the production. We use a corporate venture capital to establish investment fund. Nanjing Iron & Steel will make investment in new segments. For instance, now we have the Wuxi Dingshuo venture capital fund, and also we have the NISCO investment fund as well. For Hainan Mining, it is increasing its revenue and also profit as well. For instance, the gas output has increased by 58%, and also the revenue has increased as well. We need to look at, for instance, other our flagship companies like Wansheng Chemical, and it has finished private placement, and also it is the flame retardant leader in our domestic market. It has the world's largest continuous intelligent engineering plastic flame retardant production line, and also it has acquired 100% equity of Shandong Hanfeng. For BESINO, it focus on water disposal, and it has more than... It has a capacity of to dispose more than 6 million tons per day. It is in the preparation for a new future IPO. EASUN Technology, as I have mentioned just now, not only it focus on the domestic market and it has win other secure orders from Li Auto and also from Xiaomi Auto and Great Wall Motor. It has successfully expanded into liquid intelligent manufacturing solutions. For Jiewei Power, it is focusing on the auto battery. Here, for instance, if you look at the number of orders, number of customers, it is quite satisfactory. It has now opened five production sites in Tianjin, Yancheng, Jiaxing, Changxing and Chuzhou. It has a capacity of 3.5 GW of holding capacity and also 22 GW capacity is under construction. This is about our financials and also our performance in 2022, the first half. Now I'd like to pass the microphone back to our host today. Well, thank you, Alex, for your introduction. Now I'd like to invite our co-CEO of Fosun International, Mr. Xu Xiaoliang, to talk about our strategy. Hi, dear investors and also dear friends who cares for Fosun. Now I'd like to talk about our strategy, and also corporate governance in H1 2022. In the past six months, we see the tension in geopolitics, and also we see the resurgence in pandemic, and also we see the energy shock and also the monetary shock. We're faced with very uncertain external factors, external environment. Actually, this has put a lot of challenges in front of us. However, in such a backdrop, we need to show our resilience and we need to keep in sight our vision and also mission and to focus on our financials and also our capital health. We have demonstrated our resilience and also our capability to ride through the waves. This year is the 30-year anniversary of Fosun. Since day one, we always talk about our mission, that is to contribute to the society, and this has never changed. We need to keep always bear in mind the mission and vision of ours, and we want to create a happier life for our families worldwide and to create an ecosystem, underlined by happiness, wealth, and health for our households. Therefore, we need to talk about our strategy. Strategy is a guidance for us, and this can facilitate our business growth and also performance optimization. At the very beginning, we focus on the pharmaceutical R&D, and we enhance our capability of R&D. We also focus on Fosun Hive, and also we start the transformation of Fosun Hive. We are the leading company in terms of ESG, and also we have a focus on dual engine and also FES system. In 2021, we began to launch our FES system, that is, to accumulate the best practice from the past and also to continue to use it as an enablement for our further development. With our strategy and also the evolution of our strategy, we have achieved long-term and steady and stable growth. We have our core competency now at hand. These are the guarantees and also the basis for our success and also it is the driving force for our future development. In March, in our annual performance result announcement, we talked about our FC2M globalization ecosystem innovation and also FES 4 core capabilities. Now I'd like to use the following time to talk about in the past six months, what we are doing in these four core capabilities. First of all, if we look at globalization, we always say that we are the practitioner of a globalization, and we combine the Chinese momentum to the global resources, and we have the dual engine. Also last year, we have the Globalization 3.0, and we combine global with the local operation. Globalization provide us with the talents, capital, and also the fund we need. If we look at our global operation in the first half of 2022, we achieved a new record. We have seen 46.8% of the sales revenue from overseas countries and the regions, and now we cover more than 30 countries. The total revenue of China Global Two-Way Empowerment is CNY 6.5 billion. Apart from the financial indicators, if we zoom in to look at operations, for instance, for NISCO, it has the new project. For Indonesia, the coking plant phase two has entered into the operation. Our BCP has been rated as one of the European climate leaders by Financial Times, and also for Fosun Pharma. It has expanded into the overseas countries, and it has established its global R&D capability. For Lanvin Group, it is promoting the SPAC listing in the New York Stock Exchange as well. At the same time, Fosun is going to build the happiness world to the families. We have our FC2M ecosystem. For all our portfolio companies, they have to improve their FC2M ecosystem focus on the customers. In terms of the system membership and at the M end and through R&D and innovation, we will continue to promote the high margin and also on the WOW products. In terms of Link, we have to build our flexible production line at the same time. We have to set up an offline BD system in order to get linked with more products and with our customers. In terms of an FC2M ecosystem improvement, we have made new breakthroughs. In terms of the membership, we have the evolution. Currently, in terms of the user operation, we have more than 414 million users. At this moment, we have covered under 50 members in terms of digitalization. For our Fosun Health, we have also seen more than CNY 1.17 billion through the deeper ecological synergy. Health segment achieved in cross-selling of CNY 1.17 billion. We have a 938 sales synergy with the ecosystem, higher than 477 last year. We have witnessed CNY 2.9 billion yuan for the Antique Gold series of Lao Miao. In terms of Link End, through our centralized operation, we have continued to improve on our purchase amount. We have achieved CNY 1.5 billion for cost reduction. Through the battle in H1, we have also seen more than 100% increase in terms of product improvement. In H1, we have seen the investment in science and innovation amounting to CNY 4.6 billion. We have a total of more than 1,500 authorized invention patents and more than 500 research projects in progress. In terms of our Intuitive and also robotic surgical operations, we have also made investment in more than CNY 700 million. For the NISCO, we have also been certified by the classification societies of seven countries in terms of crack arrest and steel. It is also applied to the world's super-large 24,000 TEU container ships. In terms of both operation and investment, we had a lot of experience in the past, and we haven't crystallized our experience. Step by step, we have been build our FES system. Essentially speaking, Fosun is going to make a tailor-made management system for Fosun based on our three-decade experience in terms of business operation and investment capabilities. It is hoped that we are able to develop and also duplicate our methodologies to support our sustainable growth in H1 based on FES and also based on continuous evolution. We have a deeper insight and understanding into FES. For example, investment in Wolves is also the demonstration of our FES capabilities. At the same time, these experience can be used to empower other portfolio companies. After our investment in Wolves, we set up our professional team to operate and improve the football club. In the second year of the football club, it returned to the Premier League, and it is one of the top eight in the Europa League. It has continued to improve the value of the Wolves. At the same time, through our consolidation, we also have the brands in sports and lifestyle, including the e-gaming industry. We have also enhanced the synergies with other Fosun brands to achieve a multiplier effect. Here you can see, thanks to the FES wheels, and we can see continued growth for Wolves, for example. Fundamentally speaking, we need to have the organization to support and continued in the growth in order to build in our global happiness and assessment. We need to have a holistic and the matrix. Last year, we have set up our four committees and based on these overseas operation committees, science and technology, innovation committee, ecosystem committee, and FES committee. We have BG and P&L and vertically, and then we also have a Hive and also AMC and vertically. So here you can see that within all these horizontal and vertical matrix, we can continue to enhance our core capabilities and then through continued development. Here you can see the overseas and operation committee is trying to set up a global organization structure to synergize the global resources in order to set up the global shared center. Also for our science and technology innovation committee, it is also trying to plan the innovation strategies in order to deliver on more products and then also services in terms of innovation. It is also going to harmonize all our technological resources. Therefore, ecosystem committee, it is also going to promote the implementation of the FC2M models. FES committee is going to extract these excellent practices and cases and implement FES empowerment projects through internal certification experts. We require different business alliance and dimensions, and also our partners with entrepreneurship in order to get connected with each other and also harmonize all these resources. After the upgrading of our partnership, we have more than 140 global partners. We also have a more than 300,000 global partners and more than 3,000 in the future entrepreneurs. We have continued to include our new partners currently. You can see that in the future, we are going to have more than 3,000 globals in different levels in addition to the partners. The recruitment and also operation will continue to be reinforced. We continue to recruit and introduce some high caliber and talents in order to improve on our outsider value. Through the challenging battles, we are going to cultivate these partners. Through the battles, we are going to identify more partners with entrepreneurship. We can continue to enlarge our partners team. Through the partnership system, we will continue to improve on our talent echelon, and then we can achieve a multiplier effect. Thanks to the high efficiency of the mechanism, and we also need to enhance our entire system. Because of this ecosystem. Okay, let's continue. Last year, in terms of the goal-driven mechanism, battle assurance mechanism, and talent development mechanism in H1, we continue with all these mechanisms. For example, we put emphasis on the OKR, and in order to make a breakthrough the KPI, and we have included OKR appraisal mechanism. At the same time, we have the monthly operation supervision mechanism, and we have to ensure the investment on these operating mechanisms and through the battles. We have also organized the rotation system to nurture our young talents. Globally speaking, we have set up our culture mechanism. In order to build our global ecosystem and our original aspiration is to make contribution to the whole world as our corporate culture will continue to enhance our systems. That is also the resilience in all the past three decades. This is also the core aspiration for ESG, because we believe that the personal improvement and also corporate improvement should be closely related with the social contribution. In all the past years, we made a new improvement and those achievements in ESG. In terms of ESG, last year, we made the commitment by 2028, we are going to achieve carbon peak. By 2050, we would like to achieve carbon neutrality. We are trying to follow on the, on the Paris Agreement in order to control the temperature increase by 0.5. In May, UNESCO has then also obtained the first SA8000 social accountability management system certificate in China's steel industry. That is then also our CSR accountability. In terms of rural doctors program and also malaria-free world. We are also making contribution to the global pandemic prevention and control. In terms of governance, based on the GRI and also the TCFD, we have also launched our TCFD reporting project in order to make disclosure and also protect the legitimate rights and interests of all the stakeholders. Thanks to our performance in ESG, we have also been highly rated by different agencies in terms of ESG. In Greater China region, I'm very honored to say that we are the only conglomerate in Greater China with an MSCI ESG rating of AA as of 2021. We also selected as a constituent of the MSCI China ESG Leaders 10-40 Index. We're also selected as a constituent of Hang Seng and also FTSE. We have an also being as the constituent of the different index. At the same time, we have an also joined the United Nations Global Compact and also the China ESG Leaders Association in order to further improve on our ESG result. That is about the governance and also strategy of Fosun International in the first half of this year. I would like to thank all the investors and also friends to join this interim results announcement. As I said just now, at the thirtieth anniversary, we have a clear objective in order to provide our global families and with any happiness and also wealthy ecosystem. In order to build the ecosystem, this is a long journey. Because everything is interconnected and it is also growing exponentially for any single company, it is impossible to move forward alone. We have to ensure the co-existence and also co-creation. We would like to join hands with all our stakeholders, including our friends and investors, analysts, and employees, et cetera, to move towards the happiness together. Thank you. Thank you, Mr. Xu Xiaoliang, for your excellent presentation. This is the end of the presentation today. Now let's move to the Q&A session. In the process of presentation, we have already received the questions from our analysts. The first question goes to Mr. Guo Guangchang. The first question comes from the analyst, and his question is that now we have to see the trend of de-globalization in the whole world. Will Fosun's globalization and global business be affected? What is the future plan for Fosun in terms of globalization? Now, the floor is yours, Mr. Guo Guangchang. Okay. First of all, I would like to thank you all and our investors and analysts. Currently, I'm in Israel, and I'm already outside of China for more than two months and visiting more than 20 countries and more than 30 cities. I have been deeply engaged in what is happening in our portfolio companies. I can feel that overall speaking for Fosun, and we are taking deep root in China, and also we are trying to go global. Going forward and even more than half of our sales revenue will come from the international market. For our Fosun's internationalization is not just to sell our products outside China or import the international products into China. We would like to leverage our global resources to create more values for our international customers. Talking about our companies and also over the process of years, and we can see they are bucking the trend. Take our Sisram, for example, and they can provide more beautiful products into our families. Also these days in Israel, they moved into the new workshop. Also for our HAL in Germany and during the COVID-19, and they have acquired Bankhaus Lampe. Also for some of our portfolio companies which have been affected, but they are in the process of recovery. Take Club Med, for example. Also in Israel, we have AHAVA and our cosmetics companies. These companies are also growing very quickly. Therefore, I would always like to say that, despite some noises of de-globalization, our globalization capabilities in Fosun is more important for China and also the whole world. We will continue to dedicate ourselves to our capabilities of globalization. In the fight against the COVID-19. You can also discover that in terms of the medical supplies purchased and from the world, and also the supply chain management, and also the global cooperation in science and technology. We believe that only the companies with the global capabilities can fully leverage the global capabilities to address the global issues and to make the whole world a better place. In terms of globalization, we continue to go deeper in terms of industrial operation and also talent and cultivation. Also we would like to consolidate our globalization in order to create more values and for our customers across the world. This is my brief answer to this question. I would like to thank you for your support once again. Thank you, Mr. Guo, for your answer. Next, the second question comes in from the analyst of Morgan Stanley, Coco Gong. We can see that Fosun Pharma has launched and more and more product lines in fighting the pandemic and then from the pharmaceutical medical diagnostics and et cetera. Currently, for the medicine authorized by MPP, how about its current manufacturing and sales? Just now we have also seen that you have signed the agreement with Genuine Biotech in January in terms of Azvudine. How about its commercialization? Mr. Chen, you are still in the Hong Kong airport. Maybe Mr. Gong, you can answer this question on his behalf. Okay, thank you for your question. Well, to begin with, before and after, and also in the middle of COVID-19, Fosun Pharma is highly responsive to improve our product mix. Here you can see Comirnaty, and also you can see the antigen testing kit. Also together with Genuine Biotech, we have signed the cooperation agreement on Azvudine, and also the authorization by MPP. At the beginning of the year, and also in Q1. We are allowed to produce the oral COVID-19 and the medicine authorized by MSD and also Pfizer. So in terms of the numbers, please still refer to the public announcement by the listed companies. For our analysts, just a kind of reminder. For all these quick response and systematic improvement on the product mix, they have fully demonstrates our global footprint and also our global operation, and also global commercialization, and also our joint R&D capabilities. We have a very high quality capabilities for partnership in India and in Africa, and also in developed countries. We have experience in terms of distribution and licensing. Thanks to all these capabilities, we are selected by the MPP for authorization. Also in terms of the quick response and for our COVID-19 detection kit. Thanks to our innovation capabilities, globally, and also our global commercialization capabilities. Thanks to these two advantages, and these are the highlights. Please pay attention to the Henlius, which is able to lay the eggs, not the eggs themselves. We are very confident from the numbers going forward. For numbers, please refer to the reports. Okay, maybe I can chime in to have an add-on point. Well, according to my understanding, actually, vaccine, of course, is very important ongoing to the future. However, in the future, when China is relaxing its policy, lifting its policy against the COVID-19, actually we can see a huge potential for our pharmaceutical and our tourism. We believe it is a high potential product. It has a great efficacy, and also it is a lower pricing. We expect it will contribute a lot to the future pharmaceutical industry and health industry of China. Thank you, Mr. Guo Guangchang and also Mr. Gong Ping. Next, the question is about our happiness segment, comes from analyst Tang Jerry from Soochow Securities. As we can see is that in the first half of 2022, the tourism industry has a very strong rebound recovery. However, domestically speaking, it is still greatly impacted by the resurgence of the pandemic. What is your outlook for the whole year? Mr. Xu Xiaoliang. Well, thank you, our dear analyst, for your great question. For FTG in H1, it has already released its performance. Its revenue is increased by 200%. Also EBITDA, it has increased to CNY 1.15 billion, and therefore from minus to a positive growth. Mainly Because the lifting of the restrictions against the COVID-19 in the overseas market. I myself is now, right now in Europe. As I can see with my own eyes, actually, in the overseas market, especially in EU, actually we see a strong rebound or recovery of the tourism, and especially now it is the summer vacation time for Europeans. Club Med has also enjoyed an increase in top line, and also it has a revenue year-on-year increase of 363%, and which is the 90% of capacity of set of 2019. Therefore, if we look at the bookings for the second half of 2022 and also the first half of 2023, it is also very satisfactory. It is 14% and also 24% higher compared with as of the 2019 levels. Therefore, we can see that we have a full-blown recovery from the overseas market, and it is sustainable. If we look at our domestic market for Atlantis Sanya, again, it is impacted by the pandemic and the revenue, the turnover is slightly down. However, if we look at the previous year, January and also February, it has a nice top line and also increase of 44% of growth. Therefore, it has a strong recovery and also a better gross margin, it is 58%. Also in one month, its turnover is CNY 235 million. Therefore, as we can see from all these indicators, Atlantis Sanya is the go-to destination for our domestic travelers. In different cities, actually, the pandemic situation is different in domestic market. One thing is for sure, once the pandemic is passed, actually, we will see a strong recovery for the tourism and also traveling industry. If we look at FOLIDAY Town Lijiang and also in Taicang City, we have two major projects, and they are under construction within our schedule. The visitors is 460 thousand. In July, its revenue is CNY 23 million. It is a record-breaking month. Our Snow World and Joyville, Taicang, and the main theme street actually has generally finished. The Snow World facilities for snow making actually is already finished installation, and it is about to be opened in the near future. We'd like to provide a brand new experience for our household consumers in China. Ongoing into the future, we see the trend for ice skiing and snow skiing, and we make preemptive strike. From now to 2024, Club Med has signed 17 hotels, plan to open 17 new hotels. Also, seven of them will be located in China. This again shows that we expect a strong rebound of the traveling industry and hotel industry in the future. Therefore, we need to make a preemptive strike and also to make a pre-planning as well. For the first question is from Daiwa Securities, from Leon Qi and also Tan Minglin. Everyone is talking about ESG and also the sustainable development of corporation. Since 2019, especially in the past several years, these two indicators has attract a lot of attention from the investors. Fosun's ESG rating is really good. Therefore, what is the goal of Fosun in terms of ESG, and how to really embed ESG and also sustainability into our industrial operation? For this question, I'd like to welcome Mr. Wang to answer it. Thank you. Thank you, our Daiwa Securities for your questions. Here I'd like to say a big thank you to all of our attendees and also audience, analysts and also investors and dear friends coming to today's, results announcement. Fosun, for ESG, we attach a great importance to ESG and also sustainability, sustainable development. For our team, that means everyone in our team in Fosun International, in the past several years, we have make strong commitment in terms of ESG. Therefore, you can see our ESG track record and also ESG rating is increasing in the past several years. For instance, for the MSCI ESG index since 2019, we are BBB, and now we are elevated. Well, December 2021 is a AA level. In the Greater China region, we are the only one to achieve the double A level of MSCI ESG index, and also for Hang Seng and also FTSE Russell, and also Standard & Poor's. For their ESG ratings, and we are increasing as well, we are demonstrating our good track record. Fosun International, we're focused on ESG and also ESG rating. This is an integral part of our operation and performance. Not only at the group level, but also at the hold co level. For each of our subsidiaries, and they focus on ESG rating as well, and also the sub-commitment or the sub-goal of each E, S, and G. We are benchmarking ourselves with the top operating companies in terms of ESG. Also we keep a good communications and also information exchange with the rating agencies as well. By doing that, our ESG going into the future, the rating will witness continuous improvement, I believe. Then the second part of the question, how to really integrate ESG and also sustainability into our industrial operation, into our daily operation. The most important thing here is that for industrial operation, we first of all look at our organizational structure, also to implement ESG related performance assessment. For these ESG indicators, they are combined with our daily operation. For instance, now we have established a under this ESG committee, we have established a ESG working group. For ESG management committee and also ESG working group, well, they take the initiatives and also they take charge of the ESG related works, and also which covers more than 20 divisions and departments. They will supervise the ESG operation of our core subsidiaries and affiliated companies. We have established the ESG internal monitoring and regulation system, and to cascade down our ESG indicators into each operational levels. By doing so, we can guarantee that we can hit our bond roadmap for ESG. Thank you very much. These are some of the measures we take. Thank you, Mr. Wang. Now is a question from analyst Hong Yuehan from CICC. What is your strategy in terms of finance? Also, what are your considerations in terms of asset portfolio optimization, and also what are the divestments you made in the first half of 2022? Mr. Gong. Well, thank you. This is a very good question. If we look at our financial strategy, it is long-term and also consistent. First of all, I'd like to talk about the portfolio optimization in terms of the asset portfolio. We take an overview, a bird's-eye view, and we need to achieve a faster development or high growth rate. We look at, for instance, revenues contributed by the overseas market and also R&D input, and also to look for the high growth opportunities. Of course, this will increase the dividend payout and also just like Fosun Pharma and also Holiday. We will have the overseas or global R&D and also commercialization capability. Currently, we have a 50-50 split of the revenues contributed by domestic and by overseas. It needs to be resilient. Especially after the COVID-19, this is just like a stress test for us. If you look at our procyclical and also countercyclical effect, actually we have achieved a very nice balance. Since 2019, we do not have the overhaul of our asset portfolio. Since 2018 and also 2019, we focus more on our subsidiary operations and management, and also to accelerate the development of our core subsidiaries. Therefore, at the group level, we need to keep a balance of investment and divestment, and also to use a credit rating as guidance, and also to increase the dividend payout by our subsidiaries, and also to exit the non-strategic and also non-core assets. We will have our own pace and also rhythm, and also at the HoldCo level, to increase our credit rating and also to reduce our debt cost and fundraising cost. We will not do major M&A at the headquarters level, at the group level. Basically we will require the core subsidiaries to form their closed loop of capital leverage and also to do the non-core, non-strategic asset exit, and also further to diversify our fundraising channels and to reduce the cost and reduce our reliance on debt fundraising. This is like the bottom line of our discipline, financial discipline. Since 2019, we began to focus on industrial operation and also subsidiary management and also operation. Since then, well, we see no major M&A happen at the headquarters level. Currently, we have achieved more divestment than investment, and for 2021 and also for the first half of 2022 as well. In 2022 H1, our divestment is much higher than investment. This is our discipline, and it is long-term. It is not a short-termism view. It's ever since 2018. Because our strategy of operation has changed since 2018, and therefore we have the corresponding changes in our financial discipline and financial strategy. Well, thank you, Mr. Gong, for your answer. Well, thank you our investors and also our audience. The 2022 Fosun International interim result announcement comes to an end for our first day. Also tomorrow morning we will have four segments giving their own reports, and we will start at 9:00 A.M. sharp. Thank you. See you tomorrow.